Diffusion Pharmaceuticals
300 East Main Stree, Suite 201
Charlottesville
Virginia
22902
United States
Tel: 434-220-0718
Fax: 434-220-0722
Website: http://www.diffusionpharma.com/
141 articles about Diffusion Pharmaceuticals
-
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
8/15/2023
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of outstanding Diffusion Common Stock (the “Reverse Split”).
-
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
3/30/2023
EIP Pharma Inc. and Diffusion Pharmaceuticals Inc., announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies.
-
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
12/16/2022
Diffusion Pharmaceuticals Inc. today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd.
-
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review
12/5/2022
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process.
-
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
11/14/2022
Diffusion Pharmaceuticals Inc. provided an update on the Company’s previously announced review and evaluation of strategic opportunities and its 2022 annual meeting of stockholders to be held on December 30, 2022.
-
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
11/14/2022
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended September 30, 2022, and provided a business update.
-
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
10/25/2022
Diffusion Pharmaceuticals Inc. announced that its Board of Directors has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactional opportunities to better leverage the potential of trans sodium crocetinate and the Company’s other assets.
-
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/11/2022
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended June 30, 2022, and provided a business update.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
7/26/2022
Diffusion Pharmaceuticals Inc. today announced that after collaboration with the United States Food and Drug Administration (“FDA”) on the design of their Phase 2 clinical trial entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (“GBM”) Patients when Administered with Standard of Care (“SOC”)”.
-
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
6/23/2022
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5/18/2022
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately.
-
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
5/17/2022
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference.
-
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
Diffusion Pharmaceuticals Inc., a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced financial results for the quarter ended March 31, 2022, and provided a business update.
-
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
5/4/2022
Diffusion Pharmaceuticals Inc. today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price.
-
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance PlanSplit Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022
4/18/2022
Diffusion Pharmaceuticals Inc. today announced that it will effect a 1-for-50 reverse stock split of its common stock.
-
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
4/11/2022
Diffusion Pharmaceuticals Inc. today announced the final participant has completed dosing in its Altitude Trial.
-
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
4/8/2022
Diffusion Pharmaceuticals Inc. today announced a postponement of its Special Meeting of Stockholders.
-
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
3/21/2022
Diffusion Pharmaceuticals Inc. today announced financial results for 2021 and provided a business update.